Wasn't even paying attention just noticed it in my account...Had a few minutes to check in...Glad to see your right on top of your game...Hopefully this will be the start of some good bank...
-------------------- The best way to predict your future is to create it.
posted
DNAPrint Genomics Expands High-Throughput Genotyping Capacity Tuesday January 31, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Jan 31, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the expansion of the Company's high-throughput genotyping capacity from 1.3 million to more than 3.9 million genotypes per day. ADVERTISEMENT
"Multiplexing and advanced automation protocols provide the flexibility to process large or small genotyping studies without compromising cost per genotype," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "Increasing high-volume throughput advances our ability to determine genotypes at economical costs to our customers and business partners. Coupled with our population
IP: Logged |
posted
when you guys predictng the climb? short term or long? i'm about to head out for the day and im not sure if i should put a sell order in. i got in at .021
-------------------- double commas and climbing
IP: Logged |
posted
**********: CMED, CRF, IFO, ABFIQ, ATAHQ, DNAG have been on ********** naked short list for 13 consecutive trading days
By M2 Last Update: 2/3/2006 9:40:00 AM Data provided by
Feb 03, 2006 (M2 PRESSWIRE via COMTEX) -- **********, www.**********, announced today that these select companies have been on the NASDAQ, AMEX and NYSE naked short threshold lists for 13 consecutive trading days: China Medical Technologies, Inc. (CMED), Cornerstone Total Return Fund, Inc. (CRF), Infosonics Corporation (IFO), American Business Financial Services, Inc. (ABFIQ), ATA Holdings Corp. (ATAHQ), DNAPrint genomics, Inc. (DNAG). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.**********/squeezetrigger.pdf.
Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. Regulation SHO mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
China Medical Technologies, Inc. (CMED) principally through its wholly owned subsidiary, Beijing Yuande Bio-Medical Engineering Co., Ltd., engages in the development, manufacture, and marketing of products for the treatment of solid cancers and benign tumors principally in the People's Republic of China. Its primary product is a high intensity focused ultrasound therapy system that is used for the noninvasive treatment of solid tumors in liver, breast, and kidney, as well as in the pelvic cavity or on bones, and tumors in the four limbs or superficial tissues. The company's products also include a chemiluminescence (ECLIA) system, which is an integrated luminescence immunoassay in-vitro diagnostics system. It offers approximately 27 types of reagents for use with the ECLIA analyzer to detect thyroid disorders; diabetes; disorders relating to reproduction and growth; and various types of tumors. The company sells its products principally through distributors. The company was established in 1999 and is headquartered in Beijing, the People's Republic of China. With 27.36 million shares outstanding and 432,050 shares declared short as of January 10th, the failure to deliver in shares of CMED has not been resolved and a buy-in is imminent.
Cornerstone Total Return Fund, Inc. (CRF) operates as a closed-end, diversified management investment company. The fund primarily invests in the equity securities. Its investment portfolio includes investments in financials, information technology, consumer discretionary, healthcare, industrials, consumer staples, energy, closed end domestic funds, telecommunication services, utilities, materials, and other sectors. Cornerstone Advisors, Inc. serves as an investment manager of the fund. Cornerstone Total Return Fund was incorporated in 1973 and is based in New York City. With 4.88 million shares outstanding and 291,740 shares declared short as of January 10th, the failure to deliver in shares of CRF has not been resolved and a buy-in is imminent.
Infosonics Corporation (IFO) distributes wireless handsets and accessories in the United States and Latin America. Its services primarily include software customization, warehousing, light assembly, and programming. The company offers its products to wireless network operators, agents, resellers, distributors, independent dealers, and retailers. Infosonics was founded by Joseph Ram in 1994. The company is headquartered in San Diego, California. With 5.33 million shares outstanding and 464,310 shares declared short as of January 10th, the failure to deliver in shares of IFO has not been resolved and a buy-in is imminent.
American Business Financial Services, Inc. (ABFIQ) together with its subsidiaries, operates as a financial services organization mainly in the eastern and central portions of the United States, as well as in the state of California. It originates, sells, and services home mortgage loans through its principal direct and indirect subsidiaries. The company was incorporated in 1985 and is based in Philadelphia, Pennsylvania. ABFS and certain of its subsidiaries filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in January 2005. The company intends to wind down its operations and dispose of its assets through the Chapter 11 plan of liquidation. The bankruptcy court approved the sale of the company's servicing operations to Ocwen Federal Bank FSB for approximately $20 million in April 2005. With 3.60 million shares outstanding and an undisclosed short position, the failure to deliver in shares of ABFIQ has not been resolved and a buy-in is possible.
ATA Holdings Corp. (ATAHQ) through its subsidiary, ATA Airlines, Inc., provides charter and scheduled airline services in the United States. It provides jet scheduled services from the Chicago-Midway Airport and the Indianapolis International Airport to destinations, such as Hawaii, Massachusetts, Mexico, Illinois, Texas, Colorado, Florida, Indiana, Nevada, California, Minnesota, New York, New Jersey, and Arizona. It also provides commercial passenger charter services to tour operators and the U.S. Military. As of December 31, 2004, its fleet consisted of 5 Lockheed L-1011s, 33 Boeing 737-800s, 15 Boeing 757-200s, 12 Boeing 757-300s, and 17 SAAB 340Bs. ATA Holdings was incorporated in 1984 and is headquartered in Indianapolis, Indiana. The company and its subsidiaries filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in October 2004 and continue to operate the business as debtors-in-possession. With 11.82 million shares outstanding and an undisclosed short position, the failure to deliver in shares of ATAHQ has not been resolved and a buy-in is possible.
DNAPrint genomics, Inc. (DNAG) develops genomics-based products and services that focus on the drug development, pharmacogenomic diagnostic tests, and forensics technology and consumer genetic tests. Its primary product is PT-401, a Super EPO' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company's other products under development include PT-401, which would be targeted to patients with a genetic profile indicating their propensity; OVANOME, a genomic-based diagnostic tool that matches ovarian cancer patients with the suitable form and dose of chemotherapy; and STATINOME, a test for the cardiac drug market to determine whether patients would be good or poor responders to statins. DNAPrint also offers ANCESTRYbyDNA and EURO-DNA, both are genome-based tests that determine genetic heritage; DNAWitness, which enables forensics experts in the law enforcement field to determine genetic heritage from DNA samples obtained from crime scenes; and RETINONE, another forensics product that can infer human iris (eye) color from DNA samples. It also provides contract genotyping services to the contract service outsourcing market. The company, formerly known as Lexington Energy, Inc., was founded by Tony Frudakis. DNAPrint genomics was incorporated in 1983 and is headquartered in Sarasota, Florida. With 149.95 million shares outstanding and an undisclosed short position, the failure to deliver in shares of DNAG has not been resolved and a buy-in is possible.
About **********
WWW.********** is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. ********** has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
********** has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.**********/squeezetrigger.pdf. The SqueezeTrigger database of nearly 600,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like ********** to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, ********** provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by **********, based upon information believed to be reliable. The information contained herein is not guaranteed by ********** to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ********** is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ********** may receive compensation in cash or shares from independent third parties or from the companies mentioned.
********** affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
********** will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ********** undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO Tel: +1 800 715 9999 e-mail: Tom*********** WWW: http://www.**********
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
-------------------- w i k i s t o c k . c o m
IP: Logged |
posted
DNAPrint Genomics Provides Ancestry Test Results for Event Organizers at Human Rights Awareness Conference
By PrimeZone Last Update: 2/7/2006 8:18:57 AM Data provided by
SARASOTA, Fla., Feb 7, 2006 (PRIMEZONE via COMTEX) -- DNAPrint Genomics, Inc. (DNAG) today announced that it has provided DNA test results to 18 persons of varying ethnic backgrounds who are leaders or organizers of the annual Human Rights Awareness Day, 2006 for the education of approximately 300 high school students in Nassau County, New York.
A workshop at Hofstra University on Thursday, Feb. 9, 2006, entitled "Who Are We Really?" will explore typical stereotypes and perceptions that people may have about each other. The workshop also will help high school juniors understand that genetically they are 99.9% the same as the person sitting next to them, although they may have very different appearances. DNAPrint's various tests define the anthropological lineages of individuals that can aid students in understanding how they are similar and different from a scientific or genealogical perspective. To demonstrate that ancestry tests often provide surprising results about genetic lineages, 18 conference planners and educators took DNAPrint's ANCESTRYby DNA(tm) 2.5, and some who qualified took the broadened EURO-DNA 1.0 tests. They plan to share their own test results with attendees of the workshop.
ANCESTRYbyDNA(tm) 2.5 is a pan-chromosomal test for genetic ancestry that reviews 176 Ancestry Informative Markers (AIMs) to provide the percentages of the major bio-geographical population groups, Sub-Saharan African, Indo-European, East Asian or Native American. The AIMs were carefully selected from large-scale screens of the human genome; and are characterized by sequences of DNA that are more prevalent in people from one area of the world than another. EURO-DNA 1.0 breaks Indo-European ancestry into four groups, reporting individuals' percentages for each: Northwestern Europe (Britain, Ireland, Scandinavia, etc.), Southeastern Europe (Italy, Greece, Turkey, etc.), Middle East and South Asia (India and Pakistan).
"The results are sometimes very surprising, but those that have taken the tests are really pleased," said Sgt. Gary Shapiro, Nassau County Police Department and moderator of the panel. "That's a common response among people who are tested. Some persons who think of themselves as Caucasian thought they would be 100 percent European, and then learn that they have some African, Asian or Native American ancestry. People who describe themselves as Black or African American sometimes discover that the African ancestry is a minority portion of their DNA."
"Avoiding racial stereotypes and learning how closely everyone is related genetically is an important topic for young adults to discuss and understand," stated Richard Gabriel, President and CEO of DNAPrint. "We are pleased to contribute to this valuable event, and we applaud the conference sponsors for undertaking a serious and significant topic that is essential for future generations to understand in order to treat each other with respect. Genealogical and anthropological lessons can also be very interesting and worthwhile from an educational perspective. DNAPrint is proud to participate in valuable public service projects and youth training like the Human Rights Awareness Day. We offer our compliments to Renaire Frieson, the conference chairperson, for putting together this important seminar series for young people."
The Human Rights Awareness Day conference is co-sponsored by the Nassau County Commission on Human Rights and the following organizations; BOCES of Nassau County, Nassau County Police Department, New York Civil Liberties Union, Office of the Nassau County District Attorney, What Color is Love, Inc. and local educators.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
posted
Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services
PrimeZone via COMTEX
Feb 21, 2006 9:22:06 AM
SARASOTA, Fla., Feb 21, 2006 (PRIMEZONE via COMTEX) --
DNAPrint Genomics, Inc. (OTCBB:DNAG) today announced that Ellipsis Biotherapeutics, Inc. will complete a record quarter of revenue generation from high volume SNP genotyping. A significant portion of the revenue came from four contracts, including a major American university, two United Kingdom academic research groups, and one Toronto based academic hospital program. Ellipsis, acquired by the Company in November 2005, conducts SNP genotyping using state-of-the-art technologies. These include single-base primer extension platforms from Beckman Coulter, Inc. and the GoldenGate(tm) platform from Illumina, Inc. With a choice of platforms and scales for performing work, Ellipsis supports companies through the entire scope of their genotyping efforts. Projects include both high throughput screening of multiple samples as well as finer mapping to clarify associations of genetic predisposition in a variety of human diseases.
"Our goal is to deliver the highest quality SNP genotyping services to the marketplace, including project development, ongoing scientific advice and data analysis and interpretation," commented Dr. Laurence Rubin, founder of Ellipsis. "Ellipsis has completed these projects on schedule and within budget. Our services have been instrumental in helping scientists publish their work in respected scientific journals. In addition to completing large volume contract services for a variety of projects, we are participating in novel research programs, which has always been part of the company's focus," he added.
"We are extremely pleased that Ellipsis Biotherapeutics has met its first major milestone and has done it with better than budgeted goals and objectives. We expect that Ellipsis will continue to contribute to our revenue growth and assist our core pursuit of pharmaceuticals and diagnostics," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc.
For further information on genotyping and other DNA services, please contact Ellipsis Biotherapeutics at (416) 586-0947.
-------------------- w i k i s t o c k . c o m
IP: Logged |
posted
SARASOTA, FL, Feb 23, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (DNAG) today announced that during a CBS Early Show broadcast, co-anchor Rene Syler described how the Company's ANCESTRYbyDNA(TM) test assisted her in determining her family's bio-geographical ancestry.
Syler was joined by her mother in an Early Show segment on Wednesday, February 22, for a discussion about their efforts to learn more about the family's past through DNA testing. Although her family's roots stretched back to Africa, Syler said she wanted to know more about her background in order to teach her children that their history does not begin with slavery.
After taking a basic mitochondrial DNA test, Syler learned that her maternal genetic ancestry included Irish, British or Scandinavian blood. These results piqued Syler's curiosity, because her mother had told her that the family had Native American lineage. Syler then turned to DNAPrint's ANCESTRYbyDNA test, which determined that her makeup was 59 percent sub-Saharan African, 25 percent European, 14 percent Native American, and 2 percent East Asian.
Syler described her reaction to the news as "blown away."
With ancestry, appearances can be deceiving. Anne Syler, the anchor's mother, said she only had a vague idea about their ancestry. "In fact, I was accepted as either French, Indian or Italian even, or Spanish," she said. "People have thought of me as all kinds of races."
DNAPrint Genomics offers a variety of tests for people interested in exploring their family heritage, including African Ancestry mtDNA test. In addition to ANCESTRYbyDNA, the Company's EURO-DNA(TM) test makes it possible for individuals of European descent to discover their hereditary profile in greater detail. ANCESTRY-MITO traces family origin along the maternal line while ANCESTRY-Y for men traces a paternal line. Ancestry kits offered by the Company come with a mouth swab that is sent back to DNAPrint's laboratory, analyzed, and the results, including genealogical history, are returned on a CD-ROM disc. The basic ANCESTRYbyDNA kit retails for $219.
-------------------- w i k i s t o c k . c o m
IP: Logged |
posted
DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences
By Market Wire Last Update: 3/3/2006 7:00:01 AM Data provided by
SARASOTA, FL, Mar 03, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (DNAG) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.
The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to ensure that patients receive the appropriate medicine and proper dosage based on a patient's genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."
"Many researchers believe that a strong link exists among drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
-------------------- w i k i s t o c k . c o m
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
up over 22% so far today.![[Big Grin]](biggrin.gif)
![[Embarrassed]](redface.gif)
![[Smile]](smile.gif)
